The Management of Classical Hodgkin's Lymphoma: Past, Present, and Future

Table 7

Summary of outcomes of nonrandomised trials of salvage treatments in relapsed and refractory Hodgkin’s lymphoma, arranged in descending order of ORR. Abbreviations: CR: complete remission; PR: partial remission; ORR: overall response rate; TRM: treatment-related mortality; DHAP: dexamethasone, cytarabine, and cisplatin; ICE: ifosfamide, carboplatin, and etoposide; IVE: ifosfamide, etoposide, and epirubicin; IV: ifosfamide, vinorelbine; Mini-BEAM: BCNU, etoposide, cytarabine, and melphalan; Dexa-BEAM: dexamethasone, carmustine, etoposide, cytarabine, and melphalan; ESHAP: etoposide, methylprednisolone, high-dose cytarabine, and cisplatin; ASHAP: doxorubicin, methylprednisolone, high-dose cytarabine, and cisplatin; MINE: mitoguazone, ifosfamide, vinorelbine, and etoposide; GVD: gemcitabine, vinorelbine, and pegylated liposomal doxorubicin; GDP: gemcitabine, dexamethasone, and cisplatin.

Regimen	No. of	CR %	PR %	ORR %	Neutropenia	Thrombocytopenia	Vomiting	TRM %
	Pts	(95% CI)	(95% CI)	(95% CI)	% Gr 3/4	% Gr 3-4	% Gr 3-4	(95% CI)
DHAP [54]	102	21	68	89	88	69	26	0
		13–29	59–77	83–95				0–4
ICE [55]	65	26	59	88	—	—	—	0
		16–39	46–71	74–92				0–5
IVE [56]	51	61	22	84	100	—	—	0
				71–93
Mini-BEAM [57]	55	51	33	84	86	60	—	2
		35–63	21–47	69–91				0.1–10
IV [58, 59]	47	45	38	83	65	0	2	—
		30–60	25–54	69–92
MINE [60]	157	—	—	75	—	—	—	5
		64–84
ASHAP [61]	56	34	36	70	100	—	—	0
GVD [62]	91	19	51	70	68	28	1	1
				60–80
GDP [63]	23	17	52	69	9	13	13	0
		5–39	31–73	52–87				0–15
Dexa-BEAM [64]	55	31	29	60	>90	>90	—	5
				46–73				1–9